Sugi Predict

Sugi Predict / Compounds / SCHEMBL447652

SCHEMBL447652

SCHEMBL447652

N#Cc1ccccc1CCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 16/20 0.62
▸ FFAR4 Q5NUL3 5/20 0.51
▸ PTGER1 P34995 1/20 0.50
▸ PTGER4 P35408 1/20 0.50
▸ PTGER3 P43115 1/20 0.50
▸ PTGER2 P43116 1/20 0.50
▸ TSPO P30536 1/20 0.49
▸ DRD3 P35462 1/20 0.49
▸ KEAP1 Q14145 1/20 0.48
▸ AKR1B1 P15121 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30740885 1.00 FFAR1 (0.62) FFAR1FFAR4PTGER1PTGER4PTGER3
Phenyl Propionic Acid SCHEMBL5407020 0.93 FFAR1 (0.68) FFAR1FFAR4KEAP1AKR1B1
SCHEMBL7906876 0.89 FFAR1 (0.56) FFAR1FFAR4PTGER1PTGER4PTGER3
SCHEMBL7367036 0.88 FFAR1 (0.55) FFAR1FFAR4
SCHEMBL5499472 0.84 FFAR1 (0.51) FFAR1FFAR4PTGER1PTGER4PTGER3
SCHEMBL6365366 0.84 ALDH1A1 (0.50) FFAR1
SCHEMBL2410483 0.84 FFAR1 (0.47) FFAR1FFAR4
SCHEMBL6800800 0.83 PTGER1 (0.51) FFAR1FFAR4PTGER1PTGER4PTGER3
SCHEMBL3115166 0.83 FFAR1 (0.47) FFAR1FFAR4TSPODRD3
SCHEMBL3974171 0.81 AKR1B1 (0.55) FFAR1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113214111-A Preparation method of 3- (2-cyanophenyl) propionic acid and 4-cyano-1-indanone 上海立科化学科技有限公司 2021-08-06 — — CN claimed
CN-110627683-A Preparation method of indanone intermediate 广东东阳光药业有限公司 2019-12-31 — — CN claimed
US-20260035341-A1 FTO INHIBITORS RPXDS CO LTD (CN) 2026-02-05 — — US disclosed
CN-116003434-A Macrocyclic compound and medical application thereof 中国药科大学 2023-04-25 — — CN disclosed
CN-114956933-A Marker containing isotope oxygen atom and preparation method and application thereof 清华大学 2022-08-30 — — CN disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 — — CN disclosed
EP-3020717-B1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO (JP) 2021-12-15 — — EP disclosed
CN-113214111-A Preparation method of 3- (2-cyanophenyl) propionic acid and 4-cyano-1-indanone 上海立科化学科技有限公司 2021-08-06 — — CN disclosed
CN-113214111-A Preparation method of 3- (2-cyanophenyl) propionic acid and 4-cyano-1-indanone 上海立科化学科技有限公司 2021-08-06 — — CN disclosed
CN-113214111-A Preparation method of 3- (2-cyanophenyl) propionic acid and 4-cyano-1-indanone 上海立科化学科技有限公司 2021-08-06 — — CN disclosed
CN-111704559-A Method for preparing 2, 3-dihydro-1-oxo-1H-indene-4-carbonitrile 重庆医药高等专科学校 2020-09-25 — — CN disclosed
US-8299246-B2 N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses ASTRAZENECA AB (SE) 2012-10-30 — — US disclosed
US-20120214822-A1 N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES ASTRAZENECA AB (SE) 2012-08-23 — — US disclosed
US-8163905-B2 Compounds and their uses 708 ASTRAZENECA AB (SE) 2012-04-24 — — US disclosed
US-20120065214-A1 COMPOUNDS AND THEIR USES 708 ASTRAZENECA AB (SE) 2012-03-15 — — US disclosed
CN-101842361-A Pyrazinone derivatives and their use in the treatment of lung diseases ASTRAZENECA AB 2010-09-22 — — CN disclosed
EP-2170848-A1 PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES AstraZeneca AB (SE) 2010-04-07 — — EP disclosed
WO-2009020457-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-02-12 — — WO disclosed
WO-2009001132-A1 PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
US-4091010-A Process for the preparation of cyanohydrin esters SUNTECH, INC. (US) 1978-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035341-A1 FTO INHIBITORS FTO, LDLR, GPR119 FFAR1 28/4885FFAR4 312/4885PTGER1 2452/4885
US-20120065214-A1 COMPOUNDS AND THEIR USES 708 CYP3A7, CYP2C8, CYP2C18 FFAR1 1792/4885FFAR4 2389/4885PTGER1 881/4885
US-20120214822-A1 N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 FFAR1 224/4885FFAR4 422/4885PTGER1 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.